Ivonescimab is under clinical development by Akeso and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ivonescimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ivonescimab overview
Ivonescimab (Idafang) acts as an anti-neoplastic agent. It is formulated as injectable solution for intravenous route of administration. Idafang is indicated along with pemetrexed and carboplatin for the treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with positive epidermal growth factor receptor (EGFR) gene mutations who have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
Ivonescimab (AK-112) is under development for the treatment of solid tumors like renal cell carcinoma, recurrent glioblastoma, cutaneous squamous cell carcinoma, triple-negative breast cancer, metastatic melanoma, human epidermal growth factor receptor 2 negative breast cancer (HER2- Breast Cancer), small-cell lung cancer, hepatocellular carcinoma and squamous and non-squamous non-small cell lung cancer, bile duct cancer (cholangiocarcinoma), recurrent or metastatic cervical squamous cell carcinoma, endometrial cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma, recurrent or metastatic biliary tract cancers, including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer, recurrent or metastatic pancreatic ductal adenocarcinoma, esophageal squamous cell carcinoma, transitional cell carcinoma (urothelial cell carcinoma), colorectal cancer, metastatic colorectal cancer, non-small cell lung cancer, small-cell lung cancer, sarcomas and recurrent or metastatic head And neck cancer squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer. The therapeutic candidate is a bi-specific antibody targeting programmed cell death protein 1 (PD-1) and VEGF. It is administered through intravenous and intravenous drip route. It is developed based on antibody analytical (ACE) platform.
Akeso overview
Akeso is a clinical-stage biopharmaceutical company that focuses on in-house discovery and development of mono and bi-specific antibody drugs. The company’s product pipeline includes Ak101 and Ak111 targeting plaque psoriasis; Ak102 for the treatment of hypercholesterolemia; Ak104 against cancer; Ak105 for treating anlotinib; and Ak112 against solid tumors. It also offers kangfang integrated development platform (ACE Platform) which covers all drug research and development, including target verification, antibody discovery and also development functions. The company works in partnership with MERCK & CO Inc, Dawnrays Pharmaceutical Holdings Ltd, Sino Biopharmaceutical Ltd and China Biopharma. Akeso is headquartered in Zhongshan, Guangdong, China
For a complete picture of Ivonescimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
